Merck (NYSE: MRK), known as MSD outside the U.S. and Canada, announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued positive opinions recommending…
A team of researchers from City of Hope® and The University of Texas M.D. Anderson Cancer Center has shared promising safety and efficacy results from a Phase 1 trial involving…
The Family Heart Foundation, a prominent research and advocacy organization, has announced the successful completion of its Flag, Identify, Network, and Deliver™ “FIND Lp(a)” machine learning model. This groundbreaking tool…
Organon (NYSE: OGN), a global healthcare company dedicated to improving women’s health, has announced a definitive agreement to acquire Dermavant Sciences, a subsidiary of Roivant (NASDAQ: ROIV). Dermavant specializes in…
Cybin Inc. (NYSE American: CYBN) (Cboe CA: CYBN) (“Cybin” or the “Company”), a clinical-stage neuropsychiatry company focused on advancing mental healthcare through innovative, next-generation treatments, recently shared key clinical accomplishments…
Neuraptive Therapeutics, a biopharmaceutical leader specializing in innovative treatments for peripheral nerve injuries, has announced that interim topline results from their ongoing Phase 2 NEUROFUSE study will be presented at…
Takeda (TOKYO:4502/NYSE: TAK) has announced a commitment of JPY 4.6 billion (approximately USD 32 million) to five new Global Corporate Social Responsibility (CSR) partners. This investment is part of Takeda’s…
Glycomine, Inc., a biotechnology company specializing in treatments for rare diseases, has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to GLM101, a mannose-1-phosphate…
Alzprotect, a French biopharmaceutical company, has successfully completed the open-label extension (OLE) phase following its Phase 2a clinical trial of AZP2006 (ezeprogind®), a treatment for Progressive Supranuclear Palsy (PSP). The…
The report titled “CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027” has been added to ResearchAndMarkets.com’s offerings. CD137, also known as 4-1BB, has emerged as a promising target in…
Wedgewood Pharmacy has officially added molnupiravir to its formulary, offering a new option for the treatment of Feline Infectious Peritonitis (FIP). Originally developed to treat viral infections in humans, including…
Viatris Inc. (NASDAQ: VTRS, “Viatris” or the “Company”) today announced the early results of its subsidiary Utah Acquisition Sub Inc.’s (“UAS”) previously announced cash tender offer (the “Maximum Tender Offer”).…